Achieving Positive Growth, Prodia Pays Out Cash Dividend by 50% of the Net Profit in 2018

JAKARTA, 2 May 2019 –  At the Annual General Meeting of Shareholders (AGMS) of PT Prodia Widyahusada Tbk (ticker symbol: PRDA), the shareholders agree to pay out the cash dividends of Rp87.73 billion or Rp93.57 per share. The amount of the dividend payment equals to 50% of the Company's net profit in 2018, which is Rp175.45 billion. In the financial year 2018, the dividend payment increased by about Rp27.41 billion or 45.44% compared to the previous year. In the previous year, the Company paid Rp60.32 billion cash dividend or 40% of the Company’s net profit for the financial year 2017.

Managing Director of Prodia Dewi Muliaty said that the Company succeeded to maintain the positive business performance to provide an added value for the shareholders. "In line with our success in maintaining positive performance growth last year, we are committed to providing cash dividends worth 50% of the Company's net profit for the financial year 2018. We continue to carry out the various strategic initiatives which can strengthen the Company's core business and operational excellence while creating sustainable added value for the shareholders and other parties," said Dewi after the Company's Annual General Meeting of Shareholders at the Indonesia Stock Exchange (IDX) Building, Jakarta (2/5).

In 2018, the Company saw an increase in their net profit by 16.35% compared to the previous year of Rp150.80 billion. The Company's Net Income also grew by 9.12% to Rp1,599.76 billion, compared to the previous year of Rp1,466.02 billion. The Company also recorded an increase in EBITDA by 16.08%, from Rp239.05 billion in 2017 to Rp277.49 billion in 2018.

The income of each customers' segment contributed respectively to the Company's revenue. The segments of individual customer and doctor's referrals contributed approximately 32.32% and 30.01% respectively to the Company's income. Meanwhile, the contributions from the third-party referral and corporate clients were about 20.68% and 16.98% respectively to the Company's income in 2018.

In 2018, the number of tests conducted reached 15.9 million and the number of visits was 2.5 million. The number of esoteric test requests grew by 9.0%, from 474,000 tests in 2017 to 517,000 in 2018. The esoteric test revenues increased by 17.3% from Rp217.33 billion in 2017 to Rp254.86 billion in 2018 or contributed around 15.9% to the Company's income in 2018.

The esoteric test is a special examination test using the Next Generation technology to identify the risks or to diagnose diseases. In accordance with the Company's aspirations to build capabilities in personalized medicine through the latest generation of technology, the Company continues to equip and develop the latest tests to meet the increasing needs of customers for quality health services.

The esoteric tests launched by Prodia include Cancer Risk (CArisk) test, which is a genomic test used to analyze more than 64 genes and 65 variants related to the risk of 9 types of cancer, i.e. breast, colon or colorectal, cervical, liver, pancreas, lung, stomach, thyroid, and uterus cancers. Other genomic risk tests developed later can be used to map the risk of cardiovascular disease, hypertension, diabetes, and autoimmune based on the genetics.

Furthermore, Prodia also provides EGFR ctCDNA gene mutation test and ultrasensitive EGFR Mutation T790M to determine the treatment of lung cancer; ProHealthy Gut for intestinal health checks, ProSafe for non-invasive prenatal testing (NIPT), which is a superior test to predict the risk of down syndrome in pregnancy.

Another strategic initiative carried out by the Company in 2018 was the Anatomical Pathology Laboratory opening which is integrated with molecular pathology. Anatomic Pathology Laboratory is a clinical laboratory specialized in providing tests on human tissue specimen (histopathology), body fluid sample (cytopathology), and protein expressions in the tissue or in human cells (immunohistochemistry). These tests are the gold standard for certain disease diagnosis. In addition, Prodia also provides a cytogenetics service for the genetics test or chromosome analysis. The cytogenetics service completes Prodia’s medical check-up services, especially in the genetics test.

On 31 May 2018, the Company's stock recording board was transfered from the Development Board to the Main Board at the Indonesia Stock Exchange (IDX). In 2018, the Company has opened a number of new branches, including Sorong, Jember, Sukabumi, Sampit, Bengkulu, and Jepara branches. In the end of 2018, Prodia had been operating the service network that incorporates 292 outlets, including 143 clinical laboratories in 34 provinces and 123 cities throughout Indonesia.

******

About PT Prodia Widyahusada Tbk.
 
Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. From the very first, Dr. Andi Widjaja, MBA along with the other founders have been committed to present the best test results with wholehearted services.

As the market leader, since 2012 Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that the quality of the test result from Prodia’s laboratory is equal to those of international laboratories.
 
On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol “PRDA”. In that corporate action, Prodia offered 187,5 million shares. Accordingly, the fund raised from the Company’s initial public offering (IPO) was Rp1.22 trillion.

Currently, Prodia has had the service network that incorporates 294 outlets, consisting of 147 clinical laboratories across 34 provinces and 124 cities in Indonesia, Prodia Health Care (PHC) - a personalized medicine-based wellness clinic - and specialty clinics, including Prodia Children’s Health Centre (PCHC), Prodia Women’s Health Centre (PWHC), and Prodia Senior Health Centre (PSHC).  

For further information, please contact: